نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - etravirine 200mg - tablet - 200 mg - active: etravirine 200mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose as a spray dried powder silicified microcrystalline cellulose magnesium stearate microcrystalline cellulose - etravirine, in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults who have evidence of viral replication and resistance to non-nucleoside transcriptase inhibitors and other antiretroviral agents.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 12mg (drug layer 1 = 3.6 mg, drug layer 2 = 8.4 mg.) - modified release tablet - 12 mg - active: paliperidone 12mg (drug layer 1 = 3.6 mg, drug layer 2 = 8.4 mg.) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega prolonged release tablet is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 3mg (drug layer 1 = 0.9 mg, drug layer 2 = 2.1 mg) - modified release tablet - 3 mg - active: paliperidone 3mg (drug layer 1 = 0.9 mg, drug layer 2 = 2.1 mg) excipient: butylated hydroxytoluene carnauba wax cellulose acetate glycerol hyetellose hypromellose iron oxide red iron oxide yellow lactose macrogol 3350 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/ or mood stabilisers (lithium and valproate).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 6mg (drug layer 1 = 1.8 mg, drug layer 2 = 4.2 mg.) - modified release tablet - 6 mg - active: paliperidone 6mg (drug layer 1 = 1.8 mg, drug layer 2 = 4.2 mg.) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega is indicated for the treatment of acute exacerbations of schizoaffective disorder as monotherapy and in combination with antidepressants and/ or mood stabilisers (lithium and valproate).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - paliperidone 9mg (drug layer 1: 2.7 mg, drug layer 2: 6.3 mg) - modified release tablet - 9 mg - active: paliperidone 9mg (drug layer 1: 2.7 mg, drug layer 2: 6.3 mg) excipient: butylated hydroxytoluene carnauba wax cellulose acetate hyetellose hypromellose iron oxide black iron oxide red macrogol 3350 macrogol 400 opacode black ns-78-17821 polyethylene oxide povidone sodium chloride stearic acid titanium dioxide - invega prolonged release tablet is indicated for the treatment of schizophrenia, including acute treatment and recurrence prevention.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ketoconazole 200mg - tablet - 200 mg - active: ketoconazole 200mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base; galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base - modified release capsule - 16 mg - active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg; galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg - modified release capsule - 24 mg - active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red iron oxide yellow opacode black s-1-277002 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg; galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg - modified release capsule - 8 mg - active: galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 0.25mg;  ;   - film coated tablet - 0.25 mg - active: risperidone 0.25mg     excipient: colloidal silicon dioxide hypromellose e-15 hypromellose e-5 iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc sodium laurilsulfate titanium dioxide